AntibodiesAssay KitscDNACulture CellsDevicesEnzymesExosomesIsotypesMedium & SerumsNATtrolPanelPCRPcr KitsReagentsRia KitsTest KitsVector & Virus

Malaria during pregnancy and transplacental transfer of Kaposi sarcoma-associated herpesvirus (KSHV) antibodies: a cohort study of Kenyan mother and child pairs

Background: Kaposi sarcoma-associated herpesvirus (KSHV) seroprevalence in sub-Saharan African kids can vary as much as 50% by age 2 years however components affecting early age of KSHV an infection should not effectively understood. Malaria throughout being pregnant has been related to hindered transplacental switch of antibodies to a number of pathogens however whether or not it impacts transplacental switch of KSHV antibodies is unknown. We aimed to find out if in utero malaria publicity decreased the switch of KSHV antibodies throughout the placenta.
Strategies: A cohort examine in Kisumu, Kenya enrolled pregnant ladies at their first antenatal clinic (ANC) go to and adopted them via supply. We included 70 KSHV-positive, HIV-negative moms and their kids. KSHV antibody ranges have been measured by ELISA (K8.1, ORF73) and multiplex assay. Transplacental switch of antibodies was measured by the wire to maternal blood ratio (CMR) of KSHV antibodies. Malaria throughout being pregnant was outlined as detection of Plasmodium falciparum (Pf) DNA at any ANC go to or supply. Amongst ladies with malaria throughout being pregnant, we examined time of final malaria an infection previous to supply and malaria incidence fee.
Outcomes: KSHV seroprevalence (constructive for K8.1 or ORF73 by ELISA) amongst pregnant ladies was 88%. Neither malaria throughout being pregnant, malaria an infection timing, nor MIR have been related to maternal supply KSHV antibody blood ranges. Maternal supply and twine blood KSHV antibody ranges have been extremely correlated however these correlations didn’t differ by malaria throughout being pregnant. KSHV transplacental antibody switch was not related to malaria throughout being pregnant, malaria an infection timing, nor MIR.
Conclusions: Malaria throughout being pregnant doesn’t seem to have an effect on switch of KSHV antibodies throughout the placenta.

Dynamic modifications in anti-SARS-CoV-2 antibodies throughout SARS-CoV-2 an infection and restoration from COVID-19

Deciphering the dynamic modifications in antibodies in opposition to SARS-CoV-2 is important for understanding the immune response in COVID-19 sufferers. Right here we analyze the laboratory findings of 1,850 sufferers to explain the dynamic modifications of the whole antibody, spike protein (S)-, receptor-binding area (RBD)-, and nucleoprotein (N)-specific immunoglobulin M (IgM) and G (IgG) ranges throughout SARS-CoV-2 an infection and restoration. The era of S-, RBD-, and N-specific IgG happens one week later in sufferers with extreme/essential COVID-19 in comparison with sufferers with gentle/average illness, whereas S- and RBD-specific IgG ranges are 1.5-fold greater in extreme/essential sufferers throughout hospitalization. The RBD-specific IgG ranges are 4-fold greater in older sufferers than in youthful sufferers throughout hospitalization.
As well as, the S- and RBD-specific IgG ranges are 2-fold greater within the recovered sufferers who’re SARS-CoV-2 RNA damaging than those that are RNA constructive. Decrease S-, RBD-, and N-specific IgG ranges are related to a decrease lymphocyte proportion, greater neutrophil proportion, and an extended period of viral shedding. Sufferers with low antibody ranges on discharge would possibly thereby have a excessive probability of being examined constructive for SARS-CoV-2 RNA after restoration. Our examine gives necessary data for COVID-19 analysis, remedy, and vaccine growth.
Throughout the coronavirus illness 2019 (COVID-19) pandemic, many international locations skilled an infection in healthcare staff (HCW) resulting from overburdened healthcare techniques. Nevertheless, whether or not contaminated HCW purchase protecting immunity in opposition to SARS-CoV-2 is unclear. Right here, we characterised SARS-CoV-2-specific antibody responses in Norwegian HCW in a potential cohort examine.
Malaria during pregnancy and transplacental transfer of Kaposi sarcoma-associated herpesvirus (KSHV) antibodies: a cohort study of Kenyan mother and child pairs
Malaria during pregnancy and transplacental transfer of Kaposi sarcoma-associated herpesvirus (KSHV) antibodies: a cohort study of Kenyan mother and child pairs

A randomized, multicentre, open-label section II proof-of-concept trial investigating the medical efficacy and security of the addition of convalescent plasma to the usual of care in sufferers hospitalized with COVID-19: the Donated Antibodies Working in opposition to nCoV (DAWn-Plasma) trial

Background: The COVID-19 pandemic has imposed an infinite burden on well being care techniques all over the world. Up to now, the administration of convalescent plasma of sufferers having recovered from SARS and extreme influenza to sufferers actively having the illness confirmed promising results on mortality and appeared secure. Whether or not or not this additionally holds true for the novel SARS-CoV-2 virus is at present unknown.
Strategies: DAWn-Plasma is a multicentre nation-wide, randomized, open-label, section II proof-of-concept medical trial, evaluating the medical efficacy and security of the addition of convalescent plasma to the usual of care in sufferers hospitalized with COVID-19 in Belgium. Sufferers hospitalized with a confirmed analysis of COVID-19 are eligible when they’re symptomatic (i.e. medical or radiological indicators) and have been recognized with COVID-19 within the 72 h earlier than examine inclusion via a PCR (nasal/nasopharyngeal swab or bronchoalveolar lavage) or a chest-CT scan displaying options suitable with COVID-19 within the absence of an alternate analysis. Sufferers are randomized in a 2:1 ratio to both customary of care and convalescent plasma (energetic remedy group) or customary of care solely. The energetic remedy group receives 2 items of 200 to 250 mL of convalescent plasma inside 12 h after randomization, with a second administration of two items 24 to 36 h after ending the primary administration. The trial goals to incorporate 483 sufferers and can recruit from 25 centres throughout Belgium. The first endpoint is the proportion of sufferers that require mechanical air flow or have died at day 15. The primary secondary endpoints are medical standing on day 15 and day 30 after randomization, as outlined by the WHO Development 10-point ordinal scale, and security of the administration of convalescent plasma.

Rabbit Anti Human Mip-3 Alpha Polyclonal Antibody

CPBT-65216RH 0.1 mg
EUR 1057.2

Anti-Human MIP-3 Antibody

102-P66 100 µg
EUR 245.7
Description: MIP-3 is a CC chemokine that signals through the CCR1 receptor. MIP-3 chemoattracts monocytes, resting T-lymphocytes and neutrophils, but does not chemoattract activated lymphocytes. Additionally, MIP-3 has been shown to inhibit colony formation of bone marrow myeloid immature progenitors. Recombinant human MIP-3 is an 11.3 kDa protein containing 99 amino acid residues, including the four highly conserved cysteine residues present in CC chemokines.

Anti-Human MIP-3&beta

GWB-BIG766 500ug Ask for price

Anti-Human MIP-3&alpha

GWB-BIG752 500ug Ask for price

Human MIP-3 (CCL23)

MBS691802-0005mg 0.005mg
EUR 300

Human MIP-3 (CCL23)

MBS691802-002mg 0.02mg
EUR 450

Human MIP-3 (CCL23)

MBS691802-5x002mg 5x0.02mg
EUR 1725

RABBIT ANTI HUMAN MIP-1 BETA

MBS221343-01mg 0.1mg
EUR 635

RABBIT ANTI HUMAN MIP-1 BETA

MBS221343-5x01mg 5x0.1mg
EUR 2695

Rabbit Anti Human Mip-3 Beta Polyclonal Antibody,Biotin

CPBT-65217RH 50 µg
EUR 1057.2

MIP-3, CCL23, human

RC315-34 5ug
EUR 125.26

Anti-Human MIP-3 beta Antibody

101-M80 500 µg
EUR 246.75
Description: MIP-3β is a CC chemokine, expressed in the thymus, lymph nodes, and in activated bone marrow stromal cells that signals through the CCR7 receptor. MIP-3β is a chemoattractant for T and B lymphocytes, and myeloid progenitor cells. Human MIP-3β is active on murine cells. Recombinant Murine MIP-3β is a 9.2 kDa protein containing 83 amino acid residues, including the four highly conserved cysteine residues present in CC chemokines.

Anti-Human MIP-3 beta Antibody

102-P68 100 µg
EUR 245.7
Description: MIP-3β is a CC chemokine that is expressed in the thymus, lymph nodes and in activated bone marrow stromal cells and signals through the CCR7 receptor. MIP-3β is a chemoattractant for T and B lymphocytes and myeloid progenitor cells. Human MIP-3β is active on mouse cells. Recombinant human MIP-3β is an 8.8 kDa protein containing 77 amino acid residues, including the four highly conserved cysteine residues present in CC chemokines.

Anti-Human MIP-3 alpha Antibody

101-M79 500 µg
EUR 246.75
Description: MIP-3α is a CC chemokine that is expressed in the liver, lymph nodes, appendix, PBL and lung and can signal through the CCR6 receptor. MIP-3α is chemotactic towards lymphocytes and dendritic cells. Additionally, it promotes the adhesion of memory CD4+ T cells and inhibits colony formation of bone marrow myeloid immature progenitors. Human MIP-3α is an 8.0 kDa protein containing 70 amino acid residues, including the four highly conserved cysteine residues present in CC chemokines.

Anti-Human MIP-3 alpha Antibody

102-P67 100 µg
EUR 245.7
Description: MIP-3α is a CC chemokine that is expressed in the liver, lymph nodes, appendix, PBL and lung and can signal through the CCR6 receptor. MIP-3α is chemotactic towards lymphocytes and dendritic cells. Additionally, it promotes the adhesion of memory CD4+ T cells and inhibits colony formation of bone marrow myeloid immature progenitors. Recombinant human MIP-3α is an 8.0 kDa protein containing 70 amino acid residues, including the four highly conserved cysteine residues present in CC chemokines.

Mouse Anti-Human MIP-3 alpha

MBS690971-05mg 0.5mg
EUR 525

Mouse Anti-Human MIP-3 alpha

MBS690971-5x05mg 5x0.5mg
EUR 2080

Human MIP-3 beta (CCL19)

MBS691825-0005mg 0.005mg
EUR 300

Human MIP-3 beta (CCL19)

MBS691825-002mg 0.02mg
EUR 450

Human MIP-3 beta (CCL19)

MBS691825-5x002mg 5x0.02mg
EUR 1725

Human MIP-3 alpha (CCL20)

MBS691737-0005mg 0.005mg
EUR 300

Human MIP-3 alpha (CCL20)

MBS691737-002mg 0.02mg
EUR 450

Human MIP-3 alpha (CCL20)

MBS691737-5x002mg 5x0.02mg
EUR 1725

Recombinant Human MIP-3 beta

MBS7611183-005mg 0.05mg
EUR 345

Recombinant Human MIP-3 beta

MBS7611183-02mg 0.2mg
EUR 635

Recombinant Human MIP-3 beta

MBS7611183-1mg 1mg
EUR 1800

Recombinant Human MIP-3 beta

MBS7611183-5x1mg 5x1mg
EUR 6955

Recombinant Human MIP-3 (CCL23)

Z100695 20 µg
EUR 85
Description: CCL23 (MPIF-1, CK8, SCYA23), a member of the CC chemokine family, was originally isolated from a human aortic endothelial cell library and from the human monocytic cell line THP-1. It is most closely related to MIP-1 and interacts with its receptor CCR1, which is expressed on monocytes, dendritic cells, lymphocytes, and endothelial cells. Functionally, CCL23 has chemotactic activity for monocytes, DC, lymphocytes, neutrophils, osteoclast precursor cells, and endothelial cells. In contrast, CCL23 reduces the proliferation of progenitor cells giving rise to granulocyte and monocyte lineages, whereas it enhances angiogenesis of endothelial cells

Recombinant Human MIP-3 (CCL23)

Z100697 100 µg
EUR 295
Description: CCL23 (MPIF-1, CK8, SCYA23), a member of the CC chemokine family, was originally isolated from a human aortic endothelial cell library and from the human monocytic cell line THP-1. It is most closely related to MIP-1 and interacts with its receptor CCR1, which is expressed on monocytes, dendritic cells, lymphocytes, and endothelial cells. Functionally, CCL23 has chemotactic activity for monocytes, DC, lymphocytes, neutrophils, osteoclast precursor cells, and endothelial cells. In contrast, CCL23 reduces the proliferation of progenitor cells giving rise to granulocyte and monocyte lineages, whereas it enhances angiogenesis of endothelial cells

Recombinant Human MIP-3 (CCL23)

Z100699 1.0 mg
EUR 2025
Description: CCL23 (MPIF-1, CK8, SCYA23), a member of the CC chemokine family, was originally isolated from a human aortic endothelial cell library and from the human monocytic cell line THP-1. It is most closely related to MIP-1 and interacts with its receptor CCR1, which is expressed on monocytes, dendritic cells, lymphocytes, and endothelial cells. Functionally, CCL23 has chemotactic activity for monocytes, DC, lymphocytes, neutrophils, osteoclast precursor cells, and endothelial cells. In contrast, CCL23 reduces the proliferation of progenitor cells giving rise to granulocyte and monocyte lineages, whereas it enhances angiogenesis of endothelial cells

Recombinant Human MIP-3 (CCL23)

HECCP-2301 5ug Ask for price

Recombinant Human MIP-3 (CCL23)

MBS4159696-002mg 0.02mg
EUR 230

Recombinant Human MIP-3 (CCL23)

MBS4159696-01mg 0.1mg
EUR 455

Recombinant Human MIP-3 (CCL23)

MBS4159696-1mg 1mg
EUR 2455

Recombinant Human MIP-3 (CCL23)

MBS4159696-5x1mg 5x1mg
EUR 10810

Human MIP-3 (CCL23) Recombinant

MBS553177-0005mg 0.005mg
EUR 165

Human MIP-3 (CCL23) Recombinant

MBS553177-002mg 0.02mg
EUR 245

MIP-3 alpha, CCL20, human

RC315-31 5ug
EUR 125.26

MIP-3-alpha/CCL20, Human

HY-P7262 10ug
EUR 321.6

MIP-3/CCL23, human recombinant

7175-10 each
EUR 248.4

MIP-3/CCL23, human recombinant

7175-50 each
EUR 810

anti- MIP-3-beta antibody

FNab05194 100µg
EUR 606.3
Description: Antibody raised against MIP-3-beta

Anti-Human CCL20/MIP-3-alpha Antibody

MBS1569010-01mg 0.1mg
EUR 375

Anti-Human CCL20/MIP-3-alpha Antibody

MBS1569010-5x01mg 5x0.1mg
EUR 1390

Mouse Anti-Human MIP-3 alpha (beta)

MBS690310-05mg 0.5mg
EUR 525

Mouse Anti-Human MIP-3 alpha (beta)

MBS690310-5x05mg 5x0.5mg
EUR 2080

Anti-Human MIP-3 Rabbit Polyclonal Antibody

TA328391 100 µg Ask for price

Goat Anti Human Mip-1 Alpha Polyclonal Antibody

CPBT-65207GH 0.1 mg
EUR 1057.2

Human MIP-3 beta ELISA Kit

GWB-SKR155 96 Tests Ask for price

Rabbit Anti Human Mip-1 Beta Polyclonal Antibody

CPBT-65212RH 0.1 mg
EUR 1057.2

Macrophage Inflammatory Protein 3, Human (MIP-3)

MBS626987-005mg 0.05mg
EUR 420

Macrophage Inflammatory Protein 3, Human (MIP-3)

MBS626987-01mg 0.1mg
EUR 525

Macrophage Inflammatory Protein 3, Human (MIP-3)

MBS626987-5x01mg 5x0.1mg
EUR 2210

Recombinant Human MIP-3 beta (CCL19)

Z101945 20 µg
EUR 195
Description: CCL19 is a chemokine that belongs to the CC family of growth factors and signals through the CCR7 receptor. CCl19 has been shown to be expressed in the thymus, lymph nodes and in activated bone marrow stromal cells. When anti-inflammatory signals are released, expression of CCL19 gets down-regulated – specifically by IL-10.

Recombinant Human MIP-3 beta (CCL19)

Z101949 1.0 mg
EUR 3900
Description: CCL19 is a chemokine that belongs to the CC family of growth factors and signals through the CCR7 receptor. CCl19 has been shown to be expressed in the thymus, lymph nodes and in activated bone marrow stromal cells. When anti-inflammatory signals are released, expression of CCL19 gets down-regulated – specifically by IL-10.

Recombinant Human MIP-3 beta (CCL19)

MBS4159807-002mg 0.02mg
EUR 345

Recombinant Human MIP-3 beta (CCL19)

MBS4159807-1mg 1(mg)
EUR 4600

Recombinant Human MIP-3 beta (CCL19)

MBS4159807-5x1mg 5x1mg
EUR 20445

Human CCL19/ MIP-3 ELISA KIT

E42EH-62 96T/48T Ask for price

Recombinant Human MIP-3 alpha (CCL20)

Z100705 25 µg
EUR 235
Description: Macrophage inflammatory protein (MIP)-3/CCL20, also known as liver and activation-regulated chemokine (LARC) or Exodus, is a member of the CC chemokine subfamily initially noted to be expressed in human liver, lung, appendix, and tonsillar crypts. MIP-3 is selectively chemotactic for CD34(+) bone marrow cell-derived immature DCs and CD45RO(+) memory T cells that express the cognate receptor CCR6. MIP-3 produced at sites of inflammation may chemoattract CCR6-expressing immature DCs to the subepithelial region of mucosal surfaces.

Recombinant Human MIP-3 alpha (CCL20)

Z100709 1.0 mg
EUR 3900
Description: Macrophage inflammatory protein (MIP)-3/CCL20, also known as liver and activation-regulated chemokine (LARC) or Exodus, is a member of the CC chemokine subfamily initially noted to be expressed in human liver, lung, appendix, and tonsillar crypts. MIP-3 is selectively chemotactic for CD34(+) bone marrow cell-derived immature DCs and CD45RO(+) memory T cells that express the cognate receptor CCR6. MIP-3 produced at sites of inflammation may chemoattract CCR6-expressing immature DCs to the subepithelial region of mucosal surfaces.

Recombinant Human MIP-3 alpha (CCL20)

HECCP-2001 5ug Ask for price

Recombinant Human MIP-3 alpha (CCL20)

MBS4159697-0025mg 0.025mg
EUR 385

Recombinant Human MIP-3 alpha (CCL20)

MBS4159697-1mg 1(mg)
EUR 4600

Recombinant Human MIP-3 alpha (CCL20)

MBS4159697-5x1mg 5x1mg
EUR 20445

Human MIP-3 alpha (CCL20) Recombinant

MBS553195-0005mg 0.005mg
EUR 165

Human MIP-3 alpha (CCL20) Recombinant

MBS553195-0025mg 0.025mg
EUR 245

Recombinant Human MIP-3 alpha/CCL20

P1220-.005 5ug
EUR 108.8
Description: Peptides & Proteins|Recombinant Proteins

Recombinant Human MIP-3 alpha/CCL20

P1220-.1 100ug
EUR 900.8
Description: Peptides & Proteins|Recombinant Proteins

Recombinant Human MIP-3 alpha/CCL20

P1220-.5 500ug
EUR 2020.8
Description: Peptides & Proteins|Recombinant Proteins

Human MIP-3 (CCL23) Recombinant Protein

100-075 20 µg
EUR 196.35
Description: MIP-3 is a CC chemokine that signals through the CCR1 receptor. MIP-3 chemoattracts monocytes, resting T-lymphocytes and neutrophils, but does not chemoattract activated lymphocytes. Additionally, MIP-3 has been shown to inhibit colony formation of bone marrow myeloid immature progenitors. Recombinant human MIP-3 is an 11.3 kDa protein containing 99 amino acid residues, including the four highly conserved cysteine residues present in CC chemokines.

Human MIP-3 (CCL23) Recombinant Protein

100-075S 5 µg
EUR 92.4
Description: MIP-3 is a CC chemokine that signals through the CCR1 receptor. MIP-3 chemoattracts monocytes, resting T-lymphocytes and neutrophils, but does not chemoattract activated lymphocytes. Additionally, MIP-3 has been shown to inhibit colony formation of bone marrow myeloid immature progenitors. Recombinant human MIP-3 is an 11.3 kDa protein containing 99 amino acid residues, including the four highly conserved cysteine residues present in CC chemokines.

Recombinant Human MIP-3 (CCL23) Protein

PROTP55773-1 20ug
EUR 380.4
Description: MIP-3 is a CC chemokine that signals through the CCR1 receptor. MIP-3 chemoattracts monocytes, resting T-lymphocytes and neutrophils, but does not chemoattract activated lymphocytes. Additionally, MIP-3 has been shown to inhibit colony formation of bone marrow myeloid immature progenitors. Recombinant human MIP-3 is an 11.3 kDa protein containing 99 amino acid residues, including the four highly conserved cysteine residues present in CC chemokines.

Recombinant Human MIP-3/CCL23 protein

CD01279-5ug 5ug
EUR 176
Description: CCL23 is a member of CC chemokine family and is encoded by CCL23 gene located on Chr.17 in humans, where near several other CC chemokines. Highly expressed in adult lung, liver, skeletal muscle and pancreas, this protein shows strong chemotactic activity for monocytes, resting T-lymphocytes, and neutrophils, but not for activated lymphocytes. It elicits the effects by binding to CCR1. CCL23 is reported that it can be cleaved into four forms: CCL23 (19-99), CCL23 (22-99), CCL23 (27-99), CCL23 (30-99).

MIP-3/CCL23 (CHO-expressed), Human

HY-P7259 10ug
EUR 321.6

Human MIP-3 Recombinant Protein Lyophilized

IHUMIP3RLY5UG each
EUR 341
Description: Human MIP-3 Recombinant Protein Lyophilized

Human MIP-3 Recombinant Protein Lyophilized

MBS8432773-INQUIRE INQUIRE Ask for price

Anti-Human MIP-4 Antibody

102-P69 100 µg
EUR 245.7
Description: MIP-4 is a CC chemokine that is expressed in lymph nodes, lungs, placenta and bone marrow. MIP-4's primary receptor is unknown. MIP-4 chemoattracts lymphocytes, and has been shown to exert activity on both CD4+ and CD8+ T cells. Human MIP-4 is a 7.8 kDa protein containing 69 amino acid residues, including the four highly conserved cysteine residues present in CC chemokines.

Anti-Human MIP-5 Antibody

102-P70G 100 µg
EUR 245.7
Description: MIP-5 is a CC chemokine that is expressed in the heart, skeletal muscle and adrenal gland. MIP-5 primarily signals through he CCR1 receptor, but also has been found to bind to CCR3. MIP-5 is chemotactic towards T cells and monocytes. Recombinant human MIP-5 is a 10.1 kDa protein containing 92 amino acid residues, including the four highly conserved cysteine residues present in CC chemokines

Anti-Human MIP-1&alpha

GWB-BIG72E 500ug Ask for price

Human MIP-3 Alpha/CCL20 ELISA Kit

EK5191 96 tests
EUR 599

Human MIP-3 alpha/CCL20 ELISA Kit

GWB-R8MPA6 1x96 well plate Ask for price

Human MIP-3 alpha/CCL20 ELISA Kit

RK00207 96 Tests
EUR 280

Human MIP-3 alpha/CCL20 ELISA Kit

MBS9135903-5x96Tests 5x96Tests
EUR 2615

Human MIP-3 alpha/CCL20 ELISA Kit

MBS9135903-96Tests 96Tests
EUR 570

Macrophage Inflammatory Protein 3, Human (MIP-3) (AP)

MBS6485956-01mL 0.1mL
EUR 635

Macrophage Inflammatory Protein 3, Human (MIP-3) (AP)

MBS6485956-5x01mL 5x0.1mL
EUR 2700

Macrophage Inflammatory Protein 3, Human (MIP-3) (PE)

MBS6485966-01mL 0.1mL
EUR 635

Macrophage Inflammatory Protein 3, Human (MIP-3) (PE)

MBS6485966-5x01mL 5x0.1mL
EUR 2700

Macrophage Inflammatory Protein 3, Human (MIP-3) (APC)

MBS6485957-01mL 0.1mL
EUR 635

Macrophage Inflammatory Protein 3, Human (MIP-3) (APC)

MBS6485957-5x01mL 5x0.1mL
EUR 2700

Macrophage Inflammatory Protein 3, Human (MIP-3) (HRP)

MBS6485960-01mL 0.1mL
EUR 635

Macrophage Inflammatory Protein 3, Human (MIP-3) (HRP)

MBS6485960-5x01mL 5x0.1mL
EUR 2700

Biotinylated Anti-Human MIP-3 Rabbit Polyclonal Antibody

TA328390 50 µg Ask for price

mAb anti-human MIP-1alpha

MBS592051-01mg 0.1mg
EUR 365

mAb anti-human MIP-1alpha

MBS592051-05mg 0.5mg
EUR 530

mAb anti-human MIP-1alpha

MBS592051-5x05mg 5x0.5mg
EUR 2140

mAb anti-human MIP-1alpha

MBS592087-01mg 0.1mg
EUR 365

mAb anti-human MIP-1alpha

MBS592087-05mg 0.5mg
EUR 530

mAb anti-human MIP-1alpha

MBS592087-5x05mg 5x0.5mg
EUR 2140

mAb anti-human MIP-1alpha

MBS592088-01mg 0.1mg
EUR 365

mAb anti-human MIP-1alpha

MBS592088-05mg 0.5mg
EUR 530

mAb anti-human MIP-1alpha

MBS592088-5x05mg 5x0.5mg
EUR 2140

mAb anti-human MIP-1alpha

MBS592099-01mg 0.1mg
EUR 365

mAb anti-human MIP-1alpha

MBS592099-05mg 0.5mg
EUR 530

mAb anti-human MIP-1alpha

MBS592099-5x05mg 5x0.5mg
EUR 2140

mAb anti-human MIP-1alpha

MBS592115-01mg 0.1mg
EUR 365

mAb anti-human MIP-1alpha

MBS592115-05mg 0.5mg
EUR 530

mAb anti-human MIP-1alpha

MBS592115-5x05mg 5x0.5mg
EUR 2140

mAb anti-human MIP-1alpha

MBS592125-01mg 0.1mg
EUR 365

mAb anti-human MIP-1alpha

MBS592125-05mg 0.5mg
EUR 530

mAb anti-human MIP-1alpha

MBS592125-5x05mg 5x0.5mg
EUR 2140

mAb anti-human MIP-1alpha

MBS592149-01mg 0.1mg
EUR 365

mAb anti-human MIP-1alpha

MBS592149-05mg 0.5mg
EUR 530

mAb anti-human MIP-1alpha

MBS592149-5x05mg 5x0.5mg
EUR 2140

mAb anti-human MIP-1alpha

MBS592168-01mg 0.1mg
EUR 365

mAb anti-human MIP-1alpha

MBS592168-05mg 0.5mg
EUR 530

mAb anti-human MIP-1alpha

MBS592168-5x05mg 5x0.5mg
EUR 2140

Macrophage Inflammatory Protein 3, Human (MIP-3) (FITC)

MBS6485959-01mL 0.1mL
EUR 635

Macrophage Inflammatory Protein 3, Human (MIP-3) (FITC)

MBS6485959-5x01mL 5x0.1mL
EUR 2700

Anti-Human MIP-1alpha (CCL3)

MBS550703-01mg 0.1mg
EUR 260

Anti-Human MIP-1alpha (CCL3)

MBS550703-02mg 0.2mg
EUR 335

Anti-Human MIP-3beta (CCL19)

MBS550705-01mg 0.1mg
EUR 260

Anti-Human MIP-3beta (CCL19)

MBS550705-02mg 0.2mg
EUR 335

Anti-Human MIP-3alpha (CCL20)

MBS550704-01mg 0.1mg
EUR 260

Anti-Human MIP-3alpha (CCL20)

MBS550704-02mg 0.2mg
EUR 335

Macrophage Inflammatory Protein 3, Human (MIP-3) (Biotin)

MBS6485958-01mL 0.1mL
EUR 635

Macrophage Inflammatory Protein 3, Human (MIP-3) (Biotin)

MBS6485958-5x01mL 5x0.1mL
EUR 2700

Macrophage Inflammatory Protein 3, Human (MIP-3) (Biotin)

MBS624290-0025mg 0.025mg
EUR 420

Macrophage Inflammatory Protein 3, Human (MIP-3) (Biotin)

MBS624290-005mg 0.05mg
EUR 525

Macrophage Inflammatory Protein 3, Human (MIP-3) (Biotin)

MBS624290-5x005mg 5x0.05mg
EUR 2210

Human CCL19/MIP-3 β ELISA Kit

E16HE0218 96T
EUR 833.33
Dialogue: This trial will both present assist or discourage the usage of convalescent plasma as an early intervention for the remedy of hospitalized sufferers with COVID-19 an infection.
Tara

Leave a Reply

Your email address will not be published.